CN106668862A - Fructose injection of antibiotic drug - Google Patents
Fructose injection of antibiotic drug Download PDFInfo
- Publication number
- CN106668862A CN106668862A CN201611054766.3A CN201611054766A CN106668862A CN 106668862 A CN106668862 A CN 106668862A CN 201611054766 A CN201611054766 A CN 201611054766A CN 106668862 A CN106668862 A CN 106668862A
- Authority
- CN
- China
- Prior art keywords
- injection
- antibiotic
- fructose
- agent
- fructose injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930091371 Fructose Natural products 0.000 title claims description 37
- 239000005715 Fructose Substances 0.000 title claims description 37
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title claims description 36
- 230000003115 biocidal effect Effects 0.000 title claims description 36
- 239000007924 injection Substances 0.000 title claims description 27
- 238000002347 injection Methods 0.000 title claims description 27
- 239000003814 drug Substances 0.000 title description 26
- 229940079593 drug Drugs 0.000 title description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 9
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 claims description 8
- 229960002313 ornidazole Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- -1 fleraxacin Chemical compound 0.000 claims description 6
- 229960001699 ofloxacin Drugs 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002422 lomefloxacin Drugs 0.000 claims description 4
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002625 pazufloxacin Drugs 0.000 claims description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 3
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 claims description 3
- 229960004099 azithromycin Drugs 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 3
- QBDBUKJBJJWZMG-VIFPVBQESA-N 1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-[(3s)-3-methylpiperazin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C1CN[C@@H](C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC(F)F QBDBUKJBJJWZMG-VIFPVBQESA-N 0.000 claims description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 2
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229950011431 cadrofloxacin Drugs 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229950009953 etimicin Drugs 0.000 claims description 2
- VEGXETMJINRLTH-ALRICIOSSA-N etimicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@H](O)[C@H]1O[C@@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N VEGXETMJINRLTH-ALRICIOSSA-N 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004884 fluconazole Drugs 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 229940083668 ketek Drugs 0.000 claims description 2
- 229960005287 lincomycin Drugs 0.000 claims description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003702 moxifloxacin Drugs 0.000 claims description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 2
- 229960000808 netilmicin Drugs 0.000 claims description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004062 rufloxacin Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229960004954 sparfloxacin Drugs 0.000 claims description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims description 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims 1
- UOBPHQJGWSVXFS-UHFFFAOYSA-N [O].[F] Chemical compound [O].[F] UOBPHQJGWSVXFS-UHFFFAOYSA-N 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 229960004236 pefloxacin Drugs 0.000 claims 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims 1
- 229960005053 tinidazole Drugs 0.000 claims 1
- 229960002737 fructose Drugs 0.000 description 32
- 229940090044 injection Drugs 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000003182 parenteral nutrition solution Substances 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002075 main ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229960000443 hydrochloric acid Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ONDRRTIAGBDDKP-PPHPATTJSA-N 294662-18-3 Chemical compound CC(O)C(O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 ONDRRTIAGBDDKP-PPHPATTJSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002231 fructose derivatives Chemical class 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a fructose injection of an antibiotic drug. The injection is composed of antibiotics, fructose and water. The injection also can contain proper additives. The antibiotic comprise gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin, pazufloxacin, fleroxacin, sparfloxacin, moxifloxacin, pefloxacin, rufloxacin, lomefloxacin, norfloxacin, caderofloxacin, azithromycin, telithromycin, ornidazole, secnidazole, tinidazole, metronidazole, clindamycin, lincomycin, fluconazole, etimicin, netilmicin, amikacin and medicinal acid additive salts, esterified compounds, derivatives and the like. The antibiotics are prepared into the fructose injection. Besides the advantages of convenience in use and quickness to take effect of the injection, compared with a gluconic infection, the injection provided by the invention is more easily absorbed and utilized, is more suitable for preventing bacteria and diminishing inflammation, supplying energy and supplementing body fluids for patients with diabetes, heart disease and liver disease, so that the application range of the injection is expanded.
Description
Technical field
The invention belongs to medical science neck city, is related to a series of fructose injection injection medicine of antibiotic medicines.
Background technology
Parenteral solution is a class I liquid I injection, and medicine is directly entered in liquid form in human vas, tissue or organ, medicine
Absorb fast, effect is rapid, be very suitable for rescuing urgent patient and use in the case that patient should not be administered orally.
Antibiotic is the medicine of clinical widely used anti-microbial effect, especially antibiotic injection drug, in clinic
In use, usually together injected with antibiotic medicine as a kind of carrier with glucose or sodium chloride solution and used, such as lactic acid is left
Ofloxacin in dextrose, ornidazole sodium chloride injection etc..Glucose and sodium chloride in parenteral solution is except with tune
Outside the effect of section osmotic pressure, moreover it is possible to correct the disorder of internal water and electrolyte, the acid-base balance of body fluid is adjusted, glucose can also be mended
Fill necessary nutrition, heat and moisture content.
For the medicine used with injection system, especially antibioticses glucose injection medicine, glucose solution as
A kind of pharmaceutical carrier, is oxidized in vivo carbon dioxide and water, and while supply energy, or stored in the form of glycogen, have
Removing toxic substances, the effect of liver protection, this is that a kind of good rehabilitation is supported for patient, is conducive to the recovery of body function and reduces medicine
Toxic and side effect；But due to glucose, in vivo metabolism needs to consume insulin, for diabetic and IGT person
Should not use, its scope for using is reduced to a great extent.
It is an object of the invention to provide a series of parenteral solution medicine of antibiotic so as in for adjusting the carrier of osmotic pressure
Composition has the pharmacological effect as glucose, and diabetic and IGT person can use safely.
The content of the invention
In order to achieve the above object, the present invention adopts the parenteral solution made in antibiotic with fructose soln as carrier.
Fructose for glucose isomers, with optics levorotation, also referred to as levulose, its pharmacological action and glucosyl group
This is identical, has functions that to directly feed heat, supplements body fluid and nutrition whole body, and fructose converting compares glucose for hepatic glycogen
Hurry up, and glycogen can be metabolized in the case of without insulin, therefore easily absorb than glucose, utilize, to diabetes, heart
Disease, patient's supply energy of dysfunction of liver, added body liquor ratio glucose are preferably.
The fructose injection of antibiotic of the present invention, is to inject the liquid dosage form ground antibiotic medicine for using, and its composition is at least
Including antibiotic, three kinds of compositions of fructose and water.Antibiotic is its main ingredient composition；Fructose is for adjusting the osmotic pressure of parenteral solution simultaneously
With the complementary pharmacological action of offer heat and nutrition etc.；Water, with the dissolving composition such as antibiotic and fructose, keeps as solvent
The effect of liquid dosage form.
Antibiotic is a total concept name, and not all antibiotic medicine all proper formulations are injected into fructose
Liquid.The fructose injection of antibiotic of the present invention, used as main ingredient composition, it includes following 25 kinds of antibiotic medicines to antibiotic：Plus replace
Sha Xing, lavo-ofloxacin, Ofloxacin, Ciprofloxacin, Pazufloxacin, fleraxacin, Sparfloxacin, MOXIFLOXACIN, training fluorine are husky
Star, Rufloxacin, Lomefloxacin, Norfloxacin, cadrofloxacin, azithromycin, Ketek, Ornidazole, Saikexiaozuo, for nitre
Azoles, metronidazole, clindamycin, lincomycin, Fluconazole, Etimicin, Netilmicin, amikacin.
It should be noted that pharmaceutically acceptable acid addition salts also including each of which of antibiotic medicine above, carboxylate, spreading out
Biology etc., such as lavo-ofloxacin just have a various forms of addition hydrochlorates, such as levofloxacin Lactate, lavo-ofloxacin hydrochloride,
Levofloxacin M. S. A etc.；Pazufloxacin commonly uses the addition salts Pazufloxacin Mesilate of its methanesulfonic acid；Again for example crin is mould
Have the forms such as clindamycin phosphate, Clindamycin Hydrochloride, clindamycin hydrochloride palmitate；Zitromax have lactobionic acid Ah
The forms such as miramycin, Azithromycin Sulfate.These are all familiar to the person skilled in the art, and this is no longer going to repeat them.
Those skilled in the art it will be appreciated that due to the property of each antibiotic medicine it is different, at it
In fructose injection, in order to ensure safely, effectively stablizing with each component for injection, according to the property of different antibiotic medicines
Matter, the material that other can also be added suitable, these materials are referred to as " additives ".Additives can be divided into following a few classes：
PH value conditioning agent：For adjusting the pH value of parenteral solution to increase the stability of medicine and accelerate the absorption of liquid, for example often
From hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium dihydrogen phosphate, disodium hydrogen phosphate etc.；
Solubilizer and cosolvent：The purpose of addition is the solubility in order to increase main ingredient in aqueous solvent, treats required to reach smelting
Purpose, such as conventional has Tween-80, glycerine, ethanol etc.；
Antioxidant：For the oxidizable reducing agent of a class, antioxidant and medicine simultaneously in the presence of, antioxidant occurs first anti-with oxygen
Raw, so as to protect medicine to exempt from oxidation, to ensure stablizing for medicine, such as conventional has sodium hydrogensulfite, sodium sulfite, dimension life
Plain C, sodium pyrosulfite, thiocarbamide etc.；
Metal chelating agent：For generating stable complex compound with the trace metal ion in liquid, it is to avoid metal ion is to medicine
The catalytic action of composition oxidation, for example, often select ethylenediamine tetra-acetic acid, disodium ethylene diamine tetraacetate etc.；
Inert gas：Air in for replacing liquid and packing container, it is to avoid main ingredient is aoxidized, for example, often select nitrogen, dioxy
Change carbon；
Supensoid agent and emulsifying agent：The purpose of addition be in order that the main ingredient composition of parenteral solution have height dispersiveness and stability,
For example conventional has soybean phosphatide, lecithin, Tween-80 etc.；
Anodyne：The purpose of addition be in order to mitigate using stimulation body produced due to medicine itself during parenteral solution or other
The pain that reason causes, such as often from lidocaine hydrochloride, procaine hydrochloride, anesin etc..
The above additives it is not necessary to the composition for using, but according to prepared antibiotic fructose injection
Selecting to use, it is selected property and using method is all well known to those skilled in the art.
The preparation technology flow process of the fructose injection of antibiotic of the present invention and glucose injection of the prior art or chlorine
Change sodium injection is similar, and basic operating procedure is first to prepare the fructose aqueous solution, adjusts pH value and adds and uses after other additives
Charcoal absorption thermal source, decolouring, filter and add after activated carbon antibiotic medicine and additives, dissolving, and refined filtration, filling and sealing go out
Bacterium.For a variety of antibiotic kinds, but no matter the preparation process of its fructose injection can be with different,
The antibiotic fructose injection produced with any preparation method, technological process, as long as containing antibiotic, fructose, water in its finished product
And additives, belong to the protection domain of the technology of the present invention.
Antibiotic is made as into fructose injection, except have the advantages that parenteral solution it is easy to use, rapid-action in addition to, compare
For the parenteral solution of glucose, it is more suitable for diabetes, heart disease, hepatopath and uses, expands its use range.
Specific embodiment
With two following embodiments, the group of antibiotic fructose injection of the present invention is further illustrated by its preparation process
Into it is not intended that embodiment limitation of the present invention.
The lomefloxacin hydrochloride fructose injection of embodiment 1.
Take fructose and add in right amount and be completely dissolved in appropriate water for injection, add the needle-use activated carbon of appropriate amount, stir evenly, use hydrochloric acid
Solution adjusts pH value 4~4.5, and 90 DEG C are incubated 30 minutes, and removal activity charcoal is filtered while hot；Separately take appropriate hydrochloric acid Lomefloxacin to add
In entering above-mentioned fructose filtrate, add to the full amount of water for injection, stir evenly, refined filtration potting, in 115 DEG C of pressure sterilizings 30 minutes, detection inspection
Test, pack.
In above-mentioned preparation process, activated carbon is that activated carbon is not the composition of parenteral solution for adsorbing pyrogen and decolourizing；
In addition, the inventory of control lomefloxacin hydrochloride and fructose can be obtained the parenteral solution of variable concentrations, for example, can be made into every 100ml and contain
0.2 gram of Lomefloxacin, the parenteral solution that 5 grams of fructose.
The composition of the lomefloxacin hydrochloride fructose injection is：Lomefloxacin hydrochloride, fructose, hydrochloric acid and water, wherein hydrochloric acid
For additives, play a part of to adjust pH value.
The Ornidazole fructose injection of embodiment 2.
Weigh 5 grams of Ornidazole to add after water for injection about 900ml dissolvings, add 50 grams of fructose, whisk to CL, use watery hydrochloric acid
PH value is adjusted to 4.5 or so, 0.05% needle-use activated carbon is added, 50 DEG C or so are incubated 15 minutes, decarbonization filtering, plus injection while hot
Water to 1000ml, determine solution content and pH value it is qualified after, then with 0.45 micrometer Millipore filter membrane refined filtration, inflated with nitrogen embedding in
In 100ml infusion bottles, 115 DEG C of Jing pressure sterilizings 30 minutes obtain final product per bottle of Ornidazole containing 0.5g, 5.0g
The composition of the Ornidazole fructose injection is：Ornidazole, fructose, hydrochloric acid, nitrogen and water, wherein hydrochloric acid and nitrogen are additional
Agent, is respectively pH value conditioning agent and protective gas.
Claims (4)
1. the fructose injection of antibiotic, it is characterised in that it is made up of a kind of antibiotic, fructose and water, can also be containing appropriate
Additives.
2. antibiotic fructose injection according to claim 1, it is characterised in that antibiotic includes gatifloxacin, left oxygen fluorine
Sha Xing, Ofloxacin, Ciprofloxacin, Pazufloxacin, fleraxacin, Sparfloxacin, MOXIFLOXACIN, Pefloxacin, Rufloxacin,
Lomefloxacin, Norfloxacin, cadrofloxacin, azithromycin, Ketek, Ornidazole, Saikexiaozuo, Tinidazole, metronidazole, gram
Woods mycin, lincomycin, Fluconazole, Etimicin, Netilmicin, amikacin.
3. antibiotic fructose injection according to claim 1, it is characterised in that additives include pH value conditioning agent, solubilising
Agent and cosolvent, antioxidant, metal chelating agent, inert gas, supensoid agent and emulsifying agent, anodyne.
4. the antibiotic fructose injection according to claim 1,2, it is characterised in that antibiotic adds including its pharmaceutically acceptable acid
Into salt, carboxylate, derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054766.3A CN106668862A (en) | 2016-11-25 | 2016-11-25 | Fructose injection of antibiotic drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054766.3A CN106668862A (en) | 2016-11-25 | 2016-11-25 | Fructose injection of antibiotic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106668862A true CN106668862A (en) | 2017-05-17 |
Family
ID=58867195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611054766.3A Withdrawn CN106668862A (en) | 2016-11-25 | 2016-11-25 | Fructose injection of antibiotic drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106668862A (en) |
-
2016
- 2016-11-25 CN CN201611054766.3A patent/CN106668862A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109432123B (en) | Compound electrolyte glucose injection and preparation method thereof | |
| EP0253662B1 (en) | Pharmaceutical compositions | |
| UA72735C2 (en) | Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation | |
| CN101007003A (en) | A stable torasemide injection and its preparation method | |
| CN102652744B (en) | Modified injection containing 13 compound vitamins and preparation method thereof | |
| CN112402371B (en) | Rudesiwei injection and preparation method thereof | |
| CN108324683A (en) | A kind of big infusion Edaravone Injection and its preparation process of stabilization | |
| CN1663615A (en) | Fructose injection of antibiotic medicine | |
| CN109481459B (en) | Compound electrolyte glucose injection and preparation method thereof | |
| CN108721625A (en) | The fructose injection of antibiotic medicine | |
| CN105769756B (en) | A kind of fumaric acid Sitafloxacin hydrate injection and preparation method thereof | |
| CN1559613A (en) | Medicinal invert sugar injection | |
| CN101467967B (en) | Binary solution type preparation for intravenous and intracerebral injection | |
| JP5291319B2 (en) | Heparin preparation | |
| CN106668862A (en) | Fructose injection of antibiotic drug | |
| CN1663569A (en) | Fructose injection for cardiovascular medicine | |
| CN106491528A (en) | Linezolid injection and preparation method thereof | |
| CN103083338B (en) | Synergetic compound analgin injection and preparation method thereof | |
| CN103169756B (en) | Pharmaceutical composition of water-soluble vitamins for injection, fat-soluble vitamin injection and fat emulsion injection | |
| CN102145164A (en) | IAPP (Islet Amyloid Polypeptide) analog injection with better stability | |
| CN109953943A (en) | The fructose injection of antibiotic medicine | |
| CN101721361B (en) | Pervone vincamine injection and preparation process thereof | |
| CN106902144B (en) | Preparation method of composition for injection of medium-long-chain fat emulsion, amino acid and glucose and composition | |
| CN102757471A (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN1616104A (en) | Transfusion medicine prepared from xylitol as istonic regulator and various injections separately and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170517 |